Skip to main content
Erschienen in: European Radiology 10/2014

01.10.2014 | Computed Tomography

Elevated serum CA 19-9 at screening tests: underlying conditions and role of abdominopelvic CT

Erschienen in: European Radiology | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To investigate underlying conditions of patients with elevated CA 19-9 at screening tests and to evaluate diagnostic performance of abdominopelvic CT.

Methods

One hundred and thirteen patients with elevated CA 19-9 (>37 U/ml) who underwent abdominopelvic CT in a screening program were selected. Underlying conditions were determined by reviewing all available data and follow-up records. Patients were categorized into malignancy, benign, and normal/non-related disease groups. Their mean CA 19-9 and percent of patients with CA 19-9 ≥ 100 U/ml were compared. Diagnostic sensitivity of CT for detecting underlying conditions of elevated CA 19-9 was analysed.

Results

Seventeen patients (17/113, 15 %) had 17 elevated CA 19-9-related malignancies, and 55 patients (55/113, 48.7 %) had 70 benign diseases. Mean CA 19-9 and percent of patients with CA 19-9 ≥ 100 U/ml in the malignancy group were significantly higher than in the two other groups. CT detected all except one malignant lesion with a detection sensitivity of 94.1 % (16/17). Of 70 CA 19-9-related benign diseases, CT detected 34 benign diseases (48.6 %) providing an alternative diagnosis for elevated CA 19-9.

Conclusion

Abdominopelvic CT is not only useful in detecting malignancies, but can also diagnose alternative benign causes of elevated CA 19-9 in asymptomatic screening tests.

Key Points

Fifteen percent of asymptomatic patients with elevated CA19-9 may have intra-abdominal malignancies.
Mean value of CA19-9 is different among malignant, benign, and non-related groups.
CT shows excellent sensitivity for intra-abdominal malignancies as causatives of elevated CA19-9.
CT provides alternative benign diagnoses as causatives of elevated CA19-9.
Detection of causatives of elevated CA19-9 using CT alleviates concerns and uncertainty.
Literatur
1.
Zurück zum Zitat Raffle AE (2000) Screening for the 21st century: learning from the past. Cytopathology 11:4–7PubMedCrossRef Raffle AE (2000) Screening for the 21st century: learning from the past. Cytopathology 11:4–7PubMedCrossRef
2.
Zurück zum Zitat Locker GY, Hamilton S, Harris J et al (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol Off J Am Soc Clin Oncol 24:5313–5327CrossRef Locker GY, Hamilton S, Harris J et al (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol Off J Am Soc Clin Oncol 24:5313–5327CrossRef
3.
Zurück zum Zitat Perkins GL, Slater ED, Sanders GK, Prichard JG (2003) Serum tumor markers. Am Fam Physician 68:1075–1082PubMed Perkins GL, Slater ED, Sanders GK, Prichard JG (2003) Serum tumor markers. Am Fam Physician 68:1075–1082PubMed
4.
Zurück zum Zitat Satake K, Takeuchi T, Homma T, Ozaki H (1994) CA19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience. Pancreas 9:703–706PubMedCrossRef Satake K, Takeuchi T, Homma T, Ozaki H (1994) CA19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience. Pancreas 9:703–706PubMedCrossRef
5.
Zurück zum Zitat Chang CY, Huang SP, Chiu HM, Lee YC, Chen MF, Lin JT (2006) Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan. Hepato-Gastroenterology 53:1–4PubMed Chang CY, Huang SP, Chiu HM, Lee YC, Chen MF, Lin JT (2006) Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan. Hepato-Gastroenterology 53:1–4PubMed
6.
Zurück zum Zitat Goonetilleke KS, Siriwardena AK (2007) Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33:266–270PubMedCrossRef Goonetilleke KS, Siriwardena AK (2007) Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33:266–270PubMedCrossRef
7.
Zurück zum Zitat Nouts A, Lévy P, Voitot H, Bernades P (1998) Diagnostic value of serum Ca 19-9 antigen in chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterol Clin Biol 22:152–159 [Article in French]PubMed Nouts A, Lévy P, Voitot H, Bernades P (1998) Diagnostic value of serum Ca 19-9 antigen in chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterol Clin Biol 22:152–159 [Article in French]PubMed
8.
Zurück zum Zitat Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW (2004) Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 19:182–186PubMedCrossRef Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW (2004) Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 19:182–186PubMedCrossRef
9.
Zurück zum Zitat Kim HR, Lee CH, Kim YW, Han SK, Shim YS, Yim JJ (2009) Increased CA 19-9 level in patients without malignant disease. Clin Chem Lab Med 47:750–754PubMedCrossRef Kim HR, Lee CH, Kim YW, Han SK, Shim YS, Yim JJ (2009) Increased CA 19-9 level in patients without malignant disease. Clin Chem Lab Med 47:750–754PubMedCrossRef
10.
Zurück zum Zitat Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ (2000) The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 95:204–207PubMedCrossRef Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ (2000) The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 95:204–207PubMedCrossRef
11.
Zurück zum Zitat Malaguarnera G, Paladina I, Giordano M, Malaguarnera M, Bertino G, Berretta M (2013) Serum markers of intrahepatic cholangiocarcinoma. Dis Markers 34:219–228PubMedCentralPubMedCrossRef Malaguarnera G, Paladina I, Giordano M, Malaguarnera M, Bertino G, Berretta M (2013) Serum markers of intrahepatic cholangiocarcinoma. Dis Markers 34:219–228PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Tsuji M, Kashihara T, Terada N, Mori H (1999) An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and 19. Pathol Int 49:310–317PubMedCrossRef Tsuji M, Kashihara T, Terada N, Mori H (1999) An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and 19. Pathol Int 49:310–317PubMedCrossRef
13.
Zurück zum Zitat Mann DV, Edwards R, Ho S, Lau WY, Glazer G (2000) Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 26:474–479PubMedCrossRef Mann DV, Edwards R, Ho S, Lau WY, Glazer G (2000) Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 26:474–479PubMedCrossRef
14.
Zurück zum Zitat Choi AR, Park JC, Kim JH et al (2013) High level of preoperative carbohydrate antigen 19-9 is a poor survival predictor in gastric cancer. World J Gastroenterol 19:5302–5308PubMedCentralPubMedCrossRef Choi AR, Park JC, Kim JH et al (2013) High level of preoperative carbohydrate antigen 19-9 is a poor survival predictor in gastric cancer. World J Gastroenterol 19:5302–5308PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Aoyama H, Tobaru Y, Tomiyama R et al (2007) Elevated carbohydrate antigen 19-9 caused by early colon cancer treated with endoscopic mucosal resection. Dig Dis Sci 52:2221–2224PubMedCrossRef Aoyama H, Tobaru Y, Tomiyama R et al (2007) Elevated carbohydrate antigen 19-9 caused by early colon cancer treated with endoscopic mucosal resection. Dig Dis Sci 52:2221–2224PubMedCrossRef
16.
Zurück zum Zitat Ohshio G, Ogawa K, Kudo H et al (1990) Immunohistochemical distribution of CA19-9 in normal and tumor tissues of the kidney. Urol Int 45:1–3PubMedCrossRef Ohshio G, Ogawa K, Kudo H et al (1990) Immunohistochemical distribution of CA19-9 in normal and tumor tissues of the kidney. Urol Int 45:1–3PubMedCrossRef
17.
Zurück zum Zitat Grankvist K, Ljungberg B, Rasmuson T (1997) Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the prognosis of renal-cell carcinoma. Int J Cancer 74:233–236PubMedCrossRef Grankvist K, Ljungberg B, Rasmuson T (1997) Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the prognosis of renal-cell carcinoma. Int J Cancer 74:233–236PubMedCrossRef
18.
Zurück zum Zitat Chuang CK, Liao SK (2004) Evaluation of CA19-9 as a tumor marker in urothelial malignancy. Scand J Urol Nephrol 38:359–365PubMedCrossRef Chuang CK, Liao SK (2004) Evaluation of CA19-9 as a tumor marker in urothelial malignancy. Scand J Urol Nephrol 38:359–365PubMedCrossRef
19.
Zurück zum Zitat Kato T, Hashimoto Y, Okada S, Tozawa K, Takahashi S, Kohri K (2007) Carbohydrate antigen 19-9-positive prostatic ductal adenocarcinoma effectively treated with cisplatin and gemcitabine. Int J Urol 14:1103–1106PubMedCrossRef Kato T, Hashimoto Y, Okada S, Tozawa K, Takahashi S, Kohri K (2007) Carbohydrate antigen 19-9-positive prostatic ductal adenocarcinoma effectively treated with cisplatin and gemcitabine. Int J Urol 14:1103–1106PubMedCrossRef
20.
Zurück zum Zitat Lee SY, Lee KT, Lee JK et al (2005) Long-term follow up results of intraductal papillary mucinous tumors of pancreas. J Gastroenterol Hepatol 20:1379–1384PubMedCrossRef Lee SY, Lee KT, Lee JK et al (2005) Long-term follow up results of intraductal papillary mucinous tumors of pancreas. J Gastroenterol Hepatol 20:1379–1384PubMedCrossRef
21.
Zurück zum Zitat Katsanos KH, Kitsanou M, Christodoulou DK, Tsianos EV (2002) High CA 19-9 levels in benign biliary tract diseases. Report of four cases and review of the literature. Eur J Intern Med 13:132–135PubMedCrossRef Katsanos KH, Kitsanou M, Christodoulou DK, Tsianos EV (2002) High CA 19-9 levels in benign biliary tract diseases. Report of four cases and review of the literature. Eur J Intern Med 13:132–135PubMedCrossRef
22.
Zurück zum Zitat Bertino G, Ardiri AM, Boemi P et al (2007) Meaning of elevated CA 19-9 serum levels in chronic hepatitis and HCV-related cirrhosis. Minerva Gastroenterol Dietol 53:305–309PubMed Bertino G, Ardiri AM, Boemi P et al (2007) Meaning of elevated CA 19-9 serum levels in chronic hepatitis and HCV-related cirrhosis. Minerva Gastroenterol Dietol 53:305–309PubMed
24.
Zurück zum Zitat Inaba K, Suzuki S, Yokoi Y et al (2003) Hepatic inflammatory pseudotumor mimicking intrahepatic cholangiocarcinoma: report of a case. Surg Today 33:714–717PubMedCrossRef Inaba K, Suzuki S, Yokoi Y et al (2003) Hepatic inflammatory pseudotumor mimicking intrahepatic cholangiocarcinoma: report of a case. Surg Today 33:714–717PubMedCrossRef
25.
Zurück zum Zitat Esposito G, Tempesta A, Galati MG et al (1999) Mucosal expression of carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with gastritis and gastric cancer. Cancer Detect Prev 23:116–122PubMedCrossRef Esposito G, Tempesta A, Galati MG et al (1999) Mucosal expression of carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with gastritis and gastric cancer. Cancer Detect Prev 23:116–122PubMedCrossRef
26.
Zurück zum Zitat Tsao KC, Hong JH, Wu TL, Chang PY, Sun CF, Wu JT (2007) Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis. J Clin Lab Anal 21:193–196PubMedCrossRef Tsao KC, Hong JH, Wu TL, Chang PY, Sun CF, Wu JT (2007) Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis. J Clin Lab Anal 21:193–196PubMedCrossRef
27.
Zurück zum Zitat Coskun A, Kiran G, Ozdemir O (2008) CA 19-9 can be a useful tumor marker in ovarian dermoid cysts. Clin Exp Obstet Gynecol 35:137–139PubMed Coskun A, Kiran G, Ozdemir O (2008) CA 19-9 can be a useful tumor marker in ovarian dermoid cysts. Clin Exp Obstet Gynecol 35:137–139PubMed
28.
Zurück zum Zitat Engin H, Borazan A, Aydemir S, Yilmaz A (2007) Assessment of tumor markers in patients with chronic renal failure. Turk J Cancer 37:143–147 Engin H, Borazan A, Aydemir S, Yilmaz A (2007) Assessment of tumor markers in patients with chronic renal failure. Turk J Cancer 37:143–147
29.
Zurück zum Zitat Aybek H, Aybek Z, Sinik Z, Demir S, Sancak B, Tuncay L (2006) Elevation of serum and urinary carbohydrate antigen 19-9 in benign hydronephrosis. Int J Urol 13:1380–1384PubMedCrossRef Aybek H, Aybek Z, Sinik Z, Demir S, Sancak B, Tuncay L (2006) Elevation of serum and urinary carbohydrate antigen 19-9 in benign hydronephrosis. Int J Urol 13:1380–1384PubMedCrossRef
30.
Zurück zum Zitat Gronowitz E, Pitkänen S, Kjellmer I, Heikinheimo M, Strandvik B (2003) Association between serum oncofetal antigens CA 19-9 and CA 125 and clinical status in patients with cystic fibrosis function in CF. Acta Paediatr 92:1267–1271PubMedCrossRef Gronowitz E, Pitkänen S, Kjellmer I, Heikinheimo M, Strandvik B (2003) Association between serum oncofetal antigens CA 19-9 and CA 125 and clinical status in patients with cystic fibrosis function in CF. Acta Paediatr 92:1267–1271PubMedCrossRef
31.
Zurück zum Zitat Takeshita M, Kubo O, Tajika Y, Izawa M, Kagawa M (1993) Immunohistochemical detection of carbohydrate determinant 19-9 (CA 19-9) in intracranial epidermoid and dermoid cysts. Surg Neurol 40:284–288PubMedCrossRef Takeshita M, Kubo O, Tajika Y, Izawa M, Kagawa M (1993) Immunohistochemical detection of carbohydrate determinant 19-9 (CA 19-9) in intracranial epidermoid and dermoid cysts. Surg Neurol 40:284–288PubMedCrossRef
32.
Zurück zum Zitat Parra JL, Kaplan S, Barkin JS (2005) Elevated CA 19-9 Caused by Hashimoto’s Thyroiditis: Review of the Benign Causes of Increased CA 19-9 Level. Dig Dis Sci 50:694–695PubMedCrossRef Parra JL, Kaplan S, Barkin JS (2005) Elevated CA 19-9 Caused by Hashimoto’s Thyroiditis: Review of the Benign Causes of Increased CA 19-9 Level. Dig Dis Sci 50:694–695PubMedCrossRef
33.
Zurück zum Zitat Jeon SW, Lee SR, Moon HS, Chung HW (2009) The clinical significance of serum CA 125, CA 19-9 and eosinophil levels in endometriosis. Korean J Obstet Gynecol 52:938–944 Jeon SW, Lee SR, Moon HS, Chung HW (2009) The clinical significance of serum CA 125, CA 19-9 and eosinophil levels in endometriosis. Korean J Obstet Gynecol 52:938–944
34.
Zurück zum Zitat Uygur-Bayramicli O, Dabak R, Orbay E et al (2007) Type 2 diabetes mellitus and CA 19-9 levels. World J Gastroenterol 13:5357–5359PubMed Uygur-Bayramicli O, Dabak R, Orbay E et al (2007) Type 2 diabetes mellitus and CA 19-9 levels. World J Gastroenterol 13:5357–5359PubMed
35.
Zurück zum Zitat Szekanecz E, Sándor Z, Antal-Szalmás P et al (2007) Increased production of the soluble tumor-associated antigens CA19-9, CA125, and CA15-3 in rheumatoid arthritis: potential adhesion molecules in synovial inflammation? Ann N Y Acad Sci 1108:359–371PubMedCrossRef Szekanecz E, Sándor Z, Antal-Szalmás P et al (2007) Increased production of the soluble tumor-associated antigens CA19-9, CA125, and CA15-3 in rheumatoid arthritis: potential adhesion molecules in synovial inflammation? Ann N Y Acad Sci 1108:359–371PubMedCrossRef
36.
Zurück zum Zitat Hachiya T, Koyama S, Kubo K, Sekiguchi M, Honda T (1998) Elevated serum CA19-9 level and regional lymphadenopathy in a young man with allergic bronchopulmonary aspergillosis. Intern Med 37:91–93PubMedCrossRef Hachiya T, Koyama S, Kubo K, Sekiguchi M, Honda T (1998) Elevated serum CA19-9 level and regional lymphadenopathy in a young man with allergic bronchopulmonary aspergillosis. Intern Med 37:91–93PubMedCrossRef
37.
Zurück zum Zitat Safi F, Schlosser W, Kolb G, Beger HG (1997) Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. J Gastrointest Surg 1:106–112PubMedCrossRef Safi F, Schlosser W, Kolb G, Beger HG (1997) Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. J Gastrointest Surg 1:106–112PubMedCrossRef
Metadaten
Titel
Elevated serum CA 19-9 at screening tests: underlying conditions and role of abdominopelvic CT
Publikationsdatum
01.10.2014
Erschienen in
European Radiology / Ausgabe 10/2014
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-014-3262-2

Weitere Artikel der Ausgabe 10/2014

European Radiology 10/2014 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

13.04.2024 Klinik aktuell Kongressbericht

Die Teilnehmer eines Forums beim DGIM-Kongress waren sich einig: Fehler in der Medizin sind häufig in ungeeigneten Prozessen und mangelnder Kommunikation begründet. Gespräche mit Patienten und im Team können helfen.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.